Loading stock data…
Kura Oncology, Inc. (KURA)
$12.52-0.73 (-5.51%)
Market ClosedLast close Sep 8
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kura Oncology, Inc. in the Healthcare sector is trading at $12.52 with a market capitalization of $768M. Wall Street consensus targets $32.00 (12 analysts), implying a +155.6% move over the next 12 months. The stock is currently 10% below its 52-week high of $13.90, remaining 27.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +155.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $18.27M↑ | $17.34M↓ | $20.75M↑ | $15.29M↑ | $14.11M |
| Gross Profit | $18.00M | — | — | — | $14.11M |
| Operating Income | -$78.81M↑ | -$86.27M↓ | -$80.00M↓ | -$72.67M↓ | -$64.70M |
| Net Income | -$73.33M↑ | -$81.00M↓ | -$74.12M↓ | -$66.12M↓ | -$57.43M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; D...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$768.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-273.05%
Volume
Today's trading volume
1.51M
Recent News
Kura Oncology (KURA) Stock Looks Fully Priced After Its 56% Run
Kura Oncology stock has delivered a solid 55.5% return over the past year, yet on broad valuation checks it still screens as expensive rather than a clear bargain. For investors, that combination of strong recent gains and a low value score raises questions about how much good news is already reflected in the current share price. The 55.5% 1 year gain highlights how strongly sentiment has improved toward Kura Oncology, which can leave less room for disappointment if expectations...
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase
Shares of Kura Oncology hit a 52-week closing high after CEO Troy Wilson bought $1.2 million worth of stock.
Company News for Aug 26, 2026
Companies in The News Are: DKS,KURA,NVTS,WMT